IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Cancer
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
Media Release IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the...
Hinge Bio, Inc. Chief Scientific Officer, Daniel Capon, Ph.D., to Present its GEM-DIMER™ Platform Technology at the University of Oxford, Kennedy Institute of Rheumatology’s Annual Translational Research Conference
Dr. Capon will present Hinge Bio’s innovative GEM-DIMER™ platform as an invited speaker at the “Pioneering Technology” Session at Trinity College,...
ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024
Company Anticipates Significant Sequential Growth in Quarterly Revenues Beginning in Q3 2024 and Beyond Reports Pharmaloz Growth Acceleration Has Begun...
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint...
SOPHiA DDM™ Platform Certified Under IVDR
Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland, Aug. 14, 2024 /PRNewswire/...
Colorectal Cancer and Gut Health: Insights from Dr. Richard Birkett
BOSTON, MA / ACCESSWIRE / August 13, 2024 / Colorectal cancer, a serious condition affecting the colon or rectum, is...
Verisante Technology, Inc. Announces Proposed RTO with SunRegen Healthcare AG
VANCOUVER, BC / ACCESSWIRE / August 13, 2024 / Verisante Technology, Inc. (TSX-V:VER.H) ("Verisante") is pleased to announce that it...
Alfred Health Enhances Cancer Patient Care with Oracle Health
Leading Victorian healthcare network integrates oncology and EHR solutions to deliver more informed care across its locations AUSTIN, Texas and VICTORIA, Australia,...
The Galien Foundation Announces 2024 Prix Galien USA Nominees for “Best Digital Health Solution,” “Best Medical Technology,” “Incubators, Accelerators and Equity,” and “Best Startup”
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences,...
SKT Productions Inc. Continues to Honor Dr. Stanley Taub: A Legacy of Innovation and Creativity Lives On
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- The world recently bid farewell to Dr. Stanley Taub, a true Renaissance man...
Health Advocate Again Earns NCQA Certification for HEDIS® Certified Measures
For the eighth consecutive year, the analytics underpinning the company's proprietary Health Insights Dashboard™ have been recognized for their quality and...
U.S. News & World Report Ranks John Theurer Cancer Center as the #1 Cancer Program in NJ and the Only Top 50 Cancer Program in the State
Regional Cancer Care Associates is pleased to announce the recognition of John Theurer Cancer Center as the #1 Cancer Program...
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership To Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
RADIAN's Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on...
Phase 1b/2 “RAINIER” Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidineCompany anticipates new data...
Jaguar Health Reports Second Quarter 2024 Financial Results
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net...
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with...
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...